Evidence map›Paper›PMID 40503012›Full record

ArticleMolecular therapy. Methods & clinical development2025

Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection.

Qi Guo, Keval Parikh, Jian Zhang, Alexander Brinkley, Grace Chen, Natnicha Jakramonpreeya, Anjie Zhen, Dong Sung An

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Qi GuoUCLA AIDS Institute, UCLA, Los Angeles, CA 90024, USA.
Keval ParikhUCLA AIDS Institute, UCLA, Los Angeles, CA 90024, USA.
Jian ZhangUCLA AIDS Institute, UCLA, Los Angeles, CA 90024, USA.
Alexander BrinkleyUCLA AIDS Institute, UCLA, Los Angeles, CA 90024, USA.
Grace ChenDepartment of Molecular, Cell, and Developmental Biology, UCLA, Los Angeles, CA 90095, USA.
Natnicha JakramonpreeyaUCLA AIDS Institute, UCLA, Los Angeles, CA 90024, USA.
Anjie ZhenUCLA AIDS Institute, UCLA, Los Angeles, CA 90024, USA.
Dong Sung AnUCLA AIDS Institute, UCLA, Los Angeles, CA 90024, USA.

Funding

UCLA-CDU CFARP30AI152501 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SCOTT G KITCHEN · 2022 to 2026
$15.6M
NIAID NIH HHS P30 AI152501
6 · The paper itself

Abstract

Hematopoietic stem/progenitor cell (HSPC)-based anti-HIV-1 gene therapy holds promise to provide life-long remission following a single treatment. Here we report a multi-pronged anti-HIV-1 HSPC-based gene therapy designed to defend against and attack HIV-1 infection. We developed a lentiviral vector capable of co-expressing three anti-HIV-1 genes. Two are designed to prevent infection, including a short hairpin RNA (shRNA) (CCR5sh1005) to knock down HIV-1 co-receptor CCR5 and a membrane-anchored HIV-1 fusion inhibitor (C46). The third gene is a CD4-based chimeric antigen receptor (CAR) designed to attack HIV-1-infected cells. Our vector also includes a non-signaling truncated human epidermal growth factor receptor (huEGFRt) which acts as a negative selection-based safety kill switch against transduced cells. Anti-HIV-1 vector-transduced human CD34

Indexed as

C46 membrane-anchored HIV-1 fusion inhibitorCCR5 short hairpin RNACD4-based anti-HIV-1 chimeric antigen receptorcetuximab-mediated in vivo negative selection, humanized mousehematopoietic stem/progenitor cell (HSPC)-based gene therapyHIV-1truncated human EGFR, huEGFRt

Identifiers

PMID40503012
PMCPMC12152878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.